Enfusion, Inc. (NYSE:ENFN – Get Free Report) insider Bronwen Bastone sold 10,539 shares of the firm’s stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $8.17, for a total transaction of $86,103.63. Following the sale, the insider now owns 217,154 shares of the company’s stock, valued at approximately $1,774,148.18. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Bronwen Bastone also recently made the following trade(s):
- On Thursday, June 20th, Bronwen Bastone sold 18,241 shares of Enfusion stock. The shares were sold at an average price of $8.11, for a total value of $147,934.51.
Enfusion Stock Performance
ENFN opened at $8.36 on Wednesday. Enfusion, Inc. has a fifty-two week low of $7.52 and a fifty-two week high of $11.56. The company has a market capitalization of $1.07 billion, a P/E ratio of 278.76, a P/E/G ratio of 1.93 and a beta of 0.96. The stock has a fifty day moving average of $9.11 and a 200-day moving average of $9.08.
Institutional Trading of Enfusion
Several hedge funds and other institutional investors have recently made changes to their positions in ENFN. Allspring Global Investments Holdings LLC bought a new stake in Enfusion in the first quarter valued at approximately $44,000. Tower Research Capital LLC TRC raised its position in shares of Enfusion by 680.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 9,894 shares of the company’s stock worth $96,000 after purchasing an additional 8,627 shares during the period. Barclays PLC raised its position in shares of Enfusion by 29.0% during the third quarter. Barclays PLC now owns 10,809 shares of the company’s stock worth $96,000 after purchasing an additional 2,430 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in shares of Enfusion during the first quarter worth approximately $102,000. Finally, Quadrature Capital Ltd bought a new stake in Enfusion during the first quarter worth $109,000. 81.05% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on ENFN shares. Morgan Stanley initiated coverage on Enfusion in a research note on Friday, May 10th. They issued an “overweight” rating and a $11.00 price target for the company. The Goldman Sachs Group downgraded Enfusion from a “neutral” rating to a “sell” rating and dropped their target price for the stock from $9.00 to $8.00 in a report on Wednesday, February 28th. Finally, Bank of America lifted their target price on Enfusion from $8.00 to $9.00 and gave the stock an “underperform” rating in a report on Wednesday, March 13th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $9.33.
View Our Latest Research Report on ENFN
Enfusion Company Profile
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
Featured Stories
- Five stocks we like better than Enfusion
- Where to Find Earnings Call Transcripts
- Chipotle Mexican Grill Stock Split: Where Does it Go From Here?
- How to Invest in Blue Chip Stocks
- Arm Holdings and Micron: Top 2 AI Stocks to Buy and Hold
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Best Buy Stock May Be Best Bought Before the Holiday Season
Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.